SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating Middle East tensions, including the Strait of Hormuz disruption and production cuts, initially sent oil prices soaring. However, immediate market conversation has shifted to the G7 and IEA's reported announcement of a massive strategic oil reserve release, prompting debate on whether the rally will continue or if a sharp downturn is imminent.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after resolving its legal dispute with Novo Nordisk and partnering to offer FDA-approved GLP-1 weight-loss medications on its platform, eliminating a significant bear thesis. This development has ignited strong bullish sentiment, with the community actively discussing a potential short squeeze due to high short interest and anticipating analyst upgrades.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to renewed short squeeze speculation and anticipation surrounding upcoming earnings, with community discussion highlighting favorable technical chart patterns and the company's robust cash position amid its ongoing business transformation.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is gaining attention following updates indicating clinical improvements for its epetraborole program and plans to discuss re-initiating a Phase 3 study, reversing a prior setback that caused a significant drop. This, combined with new strategic collaborations, financing, and recent insider buying, has sparked a community discussion between optimistic bulls targeting substantial gains and cautious observers anticipating further volatility.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. is trending as investors grapple with its latest earnings, revealing robust park performance and the appointment of Josh D'Amaro as the new CEO, sparking divided community discussion on the company's strategic direction, content output, and long-term valuation.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is experiencing a significant surge with high volume, fueled by aggressive short covering and institutional buying, propelling it past a key resistance level. The community is actively debating a potential short squeeze and anticipating international approvals for its pioneering TIL therapy, believing the stock is fundamentally undervalued.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant attention as bullish investors react to the CEO's recent remarks hinting at "curative outcomes" for its lead AML immunotherapy, GPS, fueling high conviction about its potential and sparking discussions of a substantial short squeeze.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

Ucore Rare Metals is a trending topic following the successful submission of its RapidSX technology's Phase 1 report to the U.S. Department of War, showcasing superior efficiency in rare earth separation. The community is actively discussing impending government investments, potential critical mineral price floors, and Ucore's pivotal role in establishing a secure, non-Chinese supply chain amid escalating global geopolitical focus on vital resources.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending due to heightened global geopolitical tensions and rising oil prices, prompting community discussion around an imminent market volatility spike and a potential correction. Many are positioning for upside in the VIX (fear gauge) as a hedge, while others caution against the leveraged ETF's inherent decay.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is a hot topic as the community actively positions for a significant downturn in crude prices. Many anticipate a reversal from recent highs, believing the surge linked to geopolitical concerns and supply worries may be overextended, with discussions focused on potential reserve releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Microvision (NASDAQ:MVIS) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Microvision from a "hold" rating to a "strong sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>Microvision’s Q4 revenue slumped 88% year-on-year to $0.2 million with a loss per share of $0.12.</li><li>D. Boral Capital analyst Jesse Sobelson downgraded MicroVision to ‘Hold’ from ‘Buy’.</li><li>The analyst said the results underscore ongoing uncertainty around near-term sales growth and continued spending pressures.&nbsp;</li></ul>MicroVision Inc. (MVIS) saw its outlook turn more cautious on Wall Street after D. Boral Capital’s downgrade raised concerns about the company’s financial trajectory and uncertain revenue prospects.&nbsp;The shift follows the firm’s fourth-quarter (Q4) results. Microvision’s Q4 revenue slumped 88% year-on-year (YoY) to $0.2 million with a loss per share (EPS) of $0.12. Both revenue and EPS missed the analysts’ consensus estimates of $3 million and a loss per share of $0.05, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Concerns Around Revenue Visibility</h2>D. Boral Capital analyst Jesse Sobelson downgraded MicroVision to ‘Hold’ from ‘Buy’ after reviewing the company’s Q4 performance and financial outlook. The analyst said the results underscore ongoing uncertainty around near-term sales growth and continued spending pressures.&nbsp;Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize. While MicroVision has positioned its technology for potential applications in advanced sensing and automotive systems, the analyst suggested that tangible commercial traction has yet to fully emerge.<a href="https://stocktwits.com/symbol/MVIS/news">MicroVision stock</a> traded over 19% lower at noon Thursday. On Stocktwits, retail sentiment around the stock shifted to ‘neutral’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_121054_png_4dd819fb08.webp" alt="MVIS’s Sentiment Meter and Message Volume as of 12:00 p.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="929" height="102"></figure><h2 class="st-heading-2">Financial Performance And Liquidity</h2>The company recorded a quarterly net loss of $37.8 million, including significant non-cash impairment and inventory charges. By comparison, the loss for the prior-year quarter stood at $31.2 million.&nbsp;The lidar developer outlined a series of operational initiatives, including early product shipments, new technology integration, and plans to streamline costs as it prepares for future growth.MicroVision ended the year with approximately $74.8 million in cash and investment securities. In February 2026, the company further strengthened its balance sheet by issuing $43 million in senior secured convertible notes under an agreement with High Trail Capital.MVIS stock has declined by more than 53% over the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-ceo-david-ellison-says-wbd-deal-positions-it-to-compete-more-effectively-globally-report/cZdQDDQRI3k">Paramount Skydance CEO David Ellison Says WBD Deal Positions It To Compete More Effectively Globally: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MicroVision logo is seen displayed on a smartphone screen. 

MVIS Plummets Over 20%: D. Boral Capital Downgrades The Stock Citing Revenue Uncertainty And Wider Q4 Loss

Analyst Jesse Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize.

Equity

Analyst Jesse Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize.


Microvision's (MVIS) "Hold" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "hold" rating on shares of Microvision in a report on Thursday...

Microvision Q4 Earnings Call Highlights

Microvision (NASDAQ:MVIS) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what Chief Executive Officer Glen DeVos described as a shift in the lidar industry...

Microvision (NASDAQ:MVIS) Releases Earnings Results, Misses Estimates By $0.07 EPS

Microvision (NASDAQ:MVIS - Get Free Report) posted its earnings results on Wednesday. The electronics maker reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.07...

Insights Ahead: Microvision's Quarterly Earnings

MicroVision Calls It Lidar 2.0, Highlights Luminar Deal and First Shipment to Europe

Microvision (NASDAQ:MVIS) executives used a recent webinar to outline what CEO Glen De Vos described as the lidar industry's shift from a technology-proving phase to a commercialization-focused era...

Microvision (MVIS) Projected to Post Earnings on Wednesday

Microvision (NASDAQ:MVIS) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

D. Boral Capital Reiterates Buy Rating for Microvision (NASDAQ:MVIS)

D. Boral Capital restated a "buy" rating and issued a $3.00 price target on shares of Microvision in a research report on Tuesday...

D. Boral Capital reissued a "buy" rating and set a $3.00 price objective on shares of Microvision in a research report on Tuesday...

MicroVision, Inc. develops and commercializes perception solutions for autonomy and mobility applications. It offers product suite, including perception software for industrial, automotive, and defense markets; MAVIN, a MEMS-based long-range sensor capable of small object detection; MOVIA, a flash-based short- to mid-range sensor; lidar sensors for non-automotive industrial markets, such as industrial, smart infrastructure, robotics, and commercial vehicles; and reference and validation software. The company also provides engineering services in connection with hardware and software products, as well as develops custom application software. In addition, it offers industrial and automotive perception systems and advanced driver-assistance systems (ADAS); and MOSAIK suite, a validation software tool for use by OEMs and Tier 1s to validate vehicle sensors for ADAS and autonomous driving applications. The company markets its products to customers directly, through trade shows, and its website. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

MVIS
Microvision Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MVIS News

MVISMicrovision Inc